Momentum Builds: FDA Clearance Boosts 23andMe; Leidos Scores $7.9B Contract
- August 31st, 2023
- 452 views
Shares of 23andMe Holding Co. (Nasdaq: ME) surged over 5% in after-hours trading as the company announced an FDA 510(k) clearance to expand its Genetic Health Risk Report related to BRCA1/BRCA2 variants. This clearance now permits 23andMe to provide information on an additional 41 variants in the BRCA1 and BRCA2 genes, which are linked to heightened risks of breast, ovarian, prostate, and pancreatic cancers.
$ME was trading at $1.22 in after-hours, up $0.12 (+10.90%) following the announcement.
In other news, Leidos Holdings, Inc. (NYSE: LDOS), a FORTUNE 500 science and technology leader, secured a significant $7.9 billion firm-fixed-price contract for an array of hardware systems, system management solutions, customizable sustainment strategies, non-personal services, and technology upgrades. The contract was awarded by the Army Contracting Command.
In after-hours, $LDOS was trading at $98.17, reflecting an increase of $0.66 (+0.68%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login